

APPROVED	O. G. FIG.
BY	
DRAFTSMAN	

Designation	Species	Epitope	Western Blot	IHC	FACS	Epitope sequence
29C11	rabbit	Pro2	Yes	yes**	n.d.	IDEKCEFLNQTDTELNSVE
31A5	rabbit	Pro3	Yes	yes**	yes	ELLQEFTDDNATTVADELK
6A1	rabbit	Pro2-3	Yes	n.d.	no	TINAIDELKECFLNIQ
14A12	rabbit	Pro3	Yes	n.d.	yes	ELLQEFTDDNATTVADELK
6B12	rabbit	Pro3	Yes	n.d.	yes	ELLQEFTDDNATTVADELK
2D3	rabbit	Pro5	Yes	n.d.	yes	SQHCYAGSGCPLEENWISKTI
16D8	rabbit	Pro3	Yes	n.d.	yes	ELLQEFTDDNATTVADELK
31-1H7	mouse	n.d.	Yes	n.d.	yes	SQHCYAGSGCPLEENWISKTI
197-1H11	mouse	Pro5	Yes	n.d.	no	SQHCYAGSGCPLEENWISKTI
32-1G11	mouse	n.d.	Yes	n.d.	yes	SQHCYAGSGCPLEENWISKTI
304-1A5	mouse	n.d.	Yes	n.d.	yes	SQHCYAGSGCPLEENWISKTI
98-1F4	mouse	n.d.	Yes	n.d.	no	SQHCYAGSGCPLEENWISKTI

Fig. 1A

pc.h.mam.6a1.cell-57.579.1.t7

CACCATGGAGACAGGCCTGCGCTGGCTCTCTGGTCGCTGTGCTCAAAGGTGTCCAGTGTCA
GTCGCTGGAGGAGTCGGCGGTGCGCTGGTAACGCCCTGGAGGATCCCTGACACTCACCTGCAC
AGTCTCTGGAATCGACCTCAGTAGCTATGGAGTGGGCTGGGTCCGCCAGGCTCCAGGGAAAGG
GGCTGGAATACATCGGAATCATTAGTAAAATTGATAACACATACTACGCGAACTGGGCGAAA
GGCGATTCAACATCTCCAAAACCTCGTGACCACGGTGGATCTGAAAATGACCAGTCTGACA
ACCGAGGACACGGCCACCTTTCTGTACCAAGGGTCTTGTGATCCCTGGGGCCCAGGCACC
CTGGTCACCGTCTCCTCAGGGCAACCTAA

pc.h.mam.16d8.cell-22.394.1.t7

CACCATGGAGACAGGCCTGCGCTGGCTCTCTGGTCGCTGTGCTCAAAGGTGTCCAGTGTCA
GTCGGTGGAGGAGTCGGGGGTGCGCTGGTACGCCCTGGAGACCCCTGACACTCACCTGCAC
AGTCTCTGGAATTCTCCCTCAGCAGCTACGACATGACCTGGTCCGCCAGGCTCCAGGGAAAGG
GCTGGAATGGATCGAACCTAGTAGTACTATTGGTAGGCCATTACGCGACCTGGGCGAGAGG
CCGATTCAACATCTCCAAAACCTCGACCACGGTGGATCTGAAAATACCAATCCGACAACCGA
GGACACGGCCACGTATTTTGGCGCAGATTCCGATTGCTGGTGA TGGTGCCCTCTGGGGCCC
AGGCACGCTGGTACCGTCTCCTCAGGGCAACCTAA

pc.h.mam.16d8.cell-21.393.2.t7

CACCATGGAGACAGGCCTGCGCTGGCTCTCTGGTCGCTGTGCTCAAAGGTGTCCAGTGTCA
GTCGGTGGAGGAGTCGGGGGTGCGCTGGTACGCCCTGGAGACCCCTGACACTCACCTGCAC
AGTCTCTGGAATTCTCCCTCAGCAGCTACGACATGACCTGGTCCGCCAGGCTCCAGGGAAAGG
GCTGGAATGGATCGAACCTAGTAGTACTATTGGTAGGCCATTACGCGACCTGGGCGAGAGG
CCGATTCAACATCTCCAAAACCTCGACCACGGTGGATCTGAAAATACCAATCCGACAACCGA
GGACACGGCCACGTATTTTGGCGCAGATTCCGATTGCTGGTGA TGGTGCCCTCTGGGGCCC
AGGCACGCTGGTACCGTCTCCTCAGGGCAACCTAA

pc.h.mam.6b12.cell-19.339.4.t7

CACCATGGAGACAGGCCTGCGCTGGCTCTCTGGTCGCTGTGCTCAAAGGTGTCCGGTGTCA
GTCGGTGGAGGAGTCGGGGGTGCGCTGGTACGCCCTGGAGACCCCTGAGGATTACCTGCAC
AGTCTCTGGAATCGACCTCAGCACCTACGACATGACCTGGTCCGCCAGGCTCCAGGGAAAGG
GACTGGAATGGATCGAACCTAGTAGTACTCTGGTACCCCTTTCCGCAATTGGGCGAGAG
GCCGATTCAACATCTCAAGACCTCGACCACGGTGGATCTGAAAATCGCACTCCGACGACCG
AAGACACTGCCACATATTTTGTGGCAGATTGCGGATTGCTCATGATGGTGCCCTCTGGGGCC
CAGGCACGCTGGTACCGTCTCCTCAGGGCAACCTAA

Fig. 1B

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

RECEIVED IN U.S. PATENT & TRADEMARK OFFICE

pc.h.mam.2d3.cell-65.576.1.f7

CCCATGGAGACAGGCCTGCGCTGGCTTCCTGGTCGCTGTGCTAAAGGTGTCCAGTGTCA
GAGCAGCTGAAGGAGTCGGAGGCCGGTACGCCCTGGACACCCCTGACACTCACCTG
CACAGTGTCTGGAATGACCTCAATATCGATGCAATGAGCTGGTCCGCCAGGCTCCAGGGA
AGGGCTGGAATTGGTACTCGTGGTGGCACATGGTCCGCCAGGCTGGCG
AAAGGCCGATTCAACATCTCAAACCCGACCACAGTGATCTGAAAATCCCAGTCCGAC
AACCGAGGACACGCCACCTATTCTGTGCCAGTATCTATTCTGATAGTGGTACTTACGAC
CTTGTGGGCCAGGCACCCGGTCACCGTCTCCTCAGGGCAACCTAA

pc.h.mam.14a12.cell-3.333.1.f7

CACCATGGAGACAGGCCTGCGCTGGCTTCCTGGTCGCTGTGCTAAAGGTGTCCAGTGTCA
GTCGGTGGAGGAGTCGGGGGTGCCCTGGTACGCCCTGGACACCCCTGACACTCACCTGCAC
CGTCTCTGGATTCTCCCTCAGCAGCCTGACATGACCTGGTCCGCCAGGCTCCAGGGAAAGGG
GCTGGAATGGATCGGAACCATTAGTAGCTGTAGCACATACTACGCAGCTGGCGAAAG
GCCGATTCAACATCTCAAACCTCGACCACGGTGGATCTGAAAATCACCAGTCCGACAACCG
AGGACACGGCACGTATTCTGTGGCAGATTGGATTGCTGGTATGGTGCCTCTGGGCC
CAGGACACGCTGGTACCGTCTCCTCAGGGCAACCTAA

pcr.g.mam.29c11.c211.11779.780com

GGAAGGCTGCGCTGGCTTCTGGTCGCTGTGCTCAGAGGTGTCCAGTGTCA
GAGTCGGGGGTNGCCTGGTAACGCCCTGGACACCCCTGANANTACCTGCACAGCCTTG
ATTTCCCTCAGTAGCTGGTAATGAGCTGGTCCGCCAGGCTCCAGGGAAAGGGCTGGAATG
GATCGGAATGATTGGTATTGGTAGTGGCACATAATANGGACCTGGCGAAAGGCCGAT
TCACCATTTCAAACCTTGACCACGGTCGATTGAAAATGACCAAGTTGACAACCGAGGA
CACGGCACCTATTGGTCAAGAGGGGTAGTTTANTTTGCTACCGCCTGTGGGCCA
GGCACCTGGTACCGTNCTCAGGGCAACCTAA

pcr.g.mam.31a5.c178.11884.780 com

TTGCAGGCTGCGTGGTTCTGGTCGCTGTGCTAAAGGTGTCCAGTGTCA
AGTCGGGGGTNGCCTGGTAACNCCTGGACACCCCTGACANTTTTGCAAAGTNNTGGAT
TTCCCTCAGCAGNTACGANATGACCTGGTCCGCCAGGCTCCAGGGAAAGGGCTGGAATGG
ATNGGAACCATTAGTANTGTGTAATGGATAATACGCACCTGGCGAAAGGCCGATTGAC
CATTTCAAACCTTGACCACCGTGGATTGAAAATCACCAGTCCGACAACCGAGGACACGG
CCAAGTATTTGTGGCAGATTGGATTGCTGGTATGGTGCCTTGGGCCGGCACGCT
GGTACCGTNCTCAGGGCAACCTAA

Fig. 1C

APPROVED	O.G. FIG.
CLASS	SUBCLASS
BY	DRAFTSMAN

TYPE SET IN 12 POINT TIMES NEW ROMAN

APPROVED	O. G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

Pro-1 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-2 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-3 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-4 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-5 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-7 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-8 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-9 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Glob-2 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

Pro-20 MKLLNVMLAALSQHCYAGSGCPPLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

N-terminal recombinant: GSGAKETAAAKFERQHMDSPDUGTDDDKAKAISPPNS.....
Peptide with Enterokinase and Thrombin cleavage sites
HCYAGSGCPPLENVISK
Mammaglobin sequence

Fig. 2

APPROVED	O.G. FIG.
BY	CLASS
CRAFTSMAN	SUBCLASS

Reactivity of Mouse Monoclonal antibodies to Mammaglobin with peptides and recombinants

Antibody	Pro2	Pro-3	Pro-4	Pro-5	Pro-6	Pro-7	Pro-8	Glob-2	Mamma-Trx	N-term	recomb	TRX
31-1H7	0.065	0.059	0.059	0.061	0.06	0.066	0.07	0.063	2.788	0.074		0.116
32-1G11	0.056	0.055	0.054	0.054	0.055	0.057	0.055	0.055	2.75	0.057		0.07
197-1H11	0.055	0.054	0.053	0.053	0.054	0.054	0.055	0.055	2.502		2.596	0.064
304-1A5	0.054	0.054	0.053	0.053	0.054	0.053	0.053	0.053	2.7		0.056	0.064
98-1F4	0.068	0.055	0.053	0.055	0.059	0.064	0.11	0.112	2.819	0.118		0.121
967	0.055	0.057	0.056	0.056	0.055	0.056	0.056	0.637	1.566	0.069		0.159
Blank	0.056	0.055	0.053	0.055	0.052	0.053	0.053	0.053	0.056	0.052		0.06

Fig. 3A

APPROVED:	O.G. FIG.
BY:	CLASS:
DRAFTER:	SUBCLASS:




Fig. 3B

APPROVED U. S. FIG.	
BY	CLASS
DRAFTSMAN	




Fig. 3C

Approved	O.G. FIG.
BY	
GRAFISMAN	

Mammaglobin rabbit monoclonal 2D3





Fig. 3D

APPROVED: C. G. FIG.

BY	CLASS	SUBCLASS
DRAFTSMAN		

Staining of permeabilized human breast tumor cell line MDA-MB415
with rabbit anti-mammaglobin monoclonal antibodies



Staining of permeabilized human breast tumor cell lines
with murine anti-mammaglobin monoclonal antibodies

Key

- Secondary alone
- Primary at 1:10

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	





Fig. 4B

Western blot analysis of Mammaglobin from MB415 cells



Mouse monoclonal: 1G11, 1F4, 1H11, 1H7, 1A5
Rabbit monoclonal: 14A12, 6B12, 2D3, 6A1
Rabbit polyclonal: 967

Rec.: bacterially expressed recombinant mammaglobin

Fig. 5

APPROVED	J.G. FIG.
6Y	CLASS SUBCLASS
DRAFTER	

IHC analysis of mammaglobin expression in normal tissue.

Normal Tissue	Mam-29C11/31A5
Breast	3-
Adrenal	0
Cervix	0
Colon	0
Duodenum	0
Gall bladder	0
Ileum	0
Kidney	0
Ovary	0
Pancreas	0
Parotid gland	0
Prostate	0
Skeletal muscle	0
Spleen	0
Testis	0

Fig. 6

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




Fig. 7A

APPROVED : O.G. FIG.
BY
CLASS
SUBCLASS




Fig. 7B

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	




Fig. 7C

APPROV'D:	O.G. FIG.
BY:	CLASS
DRAFTSMAN:	SUBCLASS




Fig. 8

APPROVED	G. G. FIG.
SY	CLASS
DRAFTSMAN	SUBCLASS

Detection of gammaglobin in sera

Serum #	Status	Western	Mammaglobin [pg/ml]	Mammaglobin [pg/ml]**		mRNA in blood*
				Sandwich ELISA 2D3 mAb capture, 29C11 secondary	Sandwich ELISA 967 Ab capture, 2D3 mAb secondary	
6 (aka 3534)	BrCA	+	4980-9600	3.8	8732	not tested
3	BrCA	nd	560-1245	2.6	2392	+
4	BrCA	nd	311-622	1.7	1443	+
12	BrCA	nd	311-622	1.5	2298	weakly +
17	BrCA	nd	149-311	0.6	1498	+
11	BrCA	nd	149-311	0.6	847	+
10	BrCA	nd	74-149	0.38	356	nd
1	Normal F	nd	38-74	0.21	2333	not tested
18	Normal M	nd	38-74	0.2	636	not tested
8	BrCA	nd	38-74	0.19	284	nd
9	Normal F	nd	38-74	0.18	188	not tested
5	Normal F	nd	<33	0.16	43	not tested
2	Normal F	nd	<33	0.14	149	not tested
7	Normal F	nd	<33	0.13	96	not tested
14	Normal F	nd	<17	0.05	18	not tested
16	Normal F	nd	<17	0.01	363	not tested
13	Normal F	nd	<17	0.01	443	not tested
15	Normal F	nd	xxx	xxx	10.8	not tested

Fig. 9

APPROVED	O.G. FIG.
CLASS	SUBCLASS
BY	
DRAFTSMAN	

1a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

2a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

3a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

4a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

5a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

6a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

7a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

8a MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVF~~MQLIYDSSLCDLF~~

peptide #	AA sequence	AA location within mmgb
1a	MKLLMVLMLAALSQHCYAGS	1-20
2a	ALSQHCYAGSGCPLLENVIS	11-30
3a	GCPPLLENVISKTINPQSKT	21-40
4a	KTINPQSKTEYKELLQFI	31-50
5a	EYKELLQEFIDDNATTNAID	41-60
6a	DDNATTNAIDELKECFLNQT	51-70
7a	ELKECFLNQTDETLSNVEVF	61-80
8a	DETL <u>SNVEVF</u> MQLIYDSSLCDLF	71-93

APPROVED U.G. FIG.
BY CLASS SUBCLASS
DRAFTSMAN:




Fig. 11A




Fig. 11B

APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

MKLLMVLMLAALSQHCYAGSGCPILLENVISKTEYKELLQEFDNNATTNAIDELKECFLNQTDETLNSNEVFMQLIYDSSLCDLF

#	Start positon	sequence (length)	score
1	2	KLLMVLMLA (9)	148
2	3	LLMVLMLAA (9)	72
3	4	LMVLMLAAL (9)	60
4	66	FLNQTDETL (9)	48
6	83	LIYDsSLCDL (10)	151
7	2	KLLMvLMLAA (10)	148
8	80	FMQLiYDSSL (10)	71
9	58	AIDE1KECFL (10)	26
10	45	LLQEfdDNA (10)	17

Fig. 12

APPROVED U.G. FIG.
BY CLASS SUBCLASS
DRAFTSMAN




Fig. 13A




Fig. 13B

APPROVED : O.G. FIG.
BY CLASS SUBCLASS
DRAFTSMAN




Fig. 13C




Fig. 14A

APPROVED	O.G. FIG.
BY	CLASS
DRAFTER	SUBCLASS




Fig. 14B




Fig. 14C




Fig. 15A

APPROVED	U.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

Normal Testes-4C
Normal Stomach-73A
Normal Stomach-137A
Normal Stomach-137A
Normal Small Intestine-66B
Normal Skin-138A
Normal Skin-60A
Normal Skeletal Muscle-128A
Normal Retina-32263
Normal Ovary-93B
Normal Lung-Clontech
Normal Lung-58A
Normal Lung-51C
Normal Liver-56A
Normal Liver-136A
Normal Kidney-69A
Normal Kidney-119A
Normal Esophagus-1375
Normal Colon-50B
Normal Brain-Clontech
Normal Brain-75A
Normal Bone Marrow-74A
Normal Bladder-S9-1
Normal Aorta-1375
Normal Prostate-131A
Normal Prostate-48B
Normal Prostate-45A
Normal Prostate-34C
Normal Prostate-117A
Prostate Tumor-40A
Prostate Tumor-35A
Prostate Tumor-135A
Prostate Tumor-115A
Ovary Tumor-120A
Lung Tumor-Squamous-96A

Fig. 15B




Fig. 16




Fig. 17

APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	SUBCLASS

D117 mgb CD4 proliferation - large assay #2
 June 2, 2000

line #	name	priming pep	media	DMSO	1A-7A	3A	5A	7A	mgb B 5A
1	AB:C9	5A	551	549	5478	454	12599	329	886
2	AB:C11	5A	155	84	13737	159	17260	137	596
3	AB:E7	5A	582	551	7815	198	12876	465	1264
4	AB:H12	5A	1309	1725	18113	965	5850	1264	295
5	AB:A7	1A-7A	588	683	15648	4500	112	22045	417
6	AB:A9	1A-7A	478	376	6939	396	426	4095	135
7	AB:B8	1A-7A	1802	1602	29047	9277	2628	5836	1177
8	AB:C9	1A-7A	2142	2258	16814	3156	2836	11635	2954
9	AB:G7	1A-7A	1553	992	7754	2004	3355	3829	492
10	AB:G9	1A-7A	1607	1577	7563	1489	3487	1752	689
11	AB:H12	1A-7A	3101	2523	23408	24070	2964	8379	2353
12	AB:H4	1A-7A	878	691	16769	674	3658	11797	478
13	CD:A4	1A-7A	124	520	20866	21542	605	3049	167
14	CD:A5	1A-7A	1439	328	12641	22252	2925	1358	563
15	CD:C7	1A-7A	76	48	67	86	39	38	40
16	AB:G7	5A	173	477	1073	184	127	499	562
17	AB:H12	5A	948	329	2001	849	1301	266	380
18	AB:C10	5A	223	181	486	254	341	97	204
19	AB:C11	5A	247	164	22726	146	15534	181	222
20	AB:G6	5A	2125	2048	2408	1616	985	1496	1217
21	AB:G7	5A	91	167	1669	162	2582	93	70
22	AB:H2	5A	411	720	21053	271	11029	157	220

Fig. 18A

APPROVED:	O.G. FIG.
BY:	CLASS
	SUBCLASS
DRAFTSMAN:	

	AB:D1	5A	222	606	204	412	276	125	57
24	AB:E9	5A	315	457	390	191	1195	177	135
25	AB:G6	1A-7A	465	295	5014	70	2148	48	455
26	AB:H4	1A-7A	545	192	14133	190	891	7519	105
27	AB:D12	1A-7A	1852	1522	13318	6496	3131	4081	946
28	AB:D1	1A-7A	1448	1614	4205	1199	1186	1822	430
29	AB:H1	1A-7A	5572	3865	18628	14627	1817	13029	1567
30	AB:A7	1A-7A	1072	525	15470	2718	907	12379	230
31	AB:B12	1A-7A	540	797	17558	703	15480	659	6354
32	AB:F7	1A-7A	551	455	8374	7694	2462	329	996
33	AB:G7	1A-7A	652	710	8278	1018	3753	2941	624
34	CD:C7	1A-7A	109	175	14322	3891	10183	628	76
35	CD:D8	1A-7A	824	2270	10295	4280	1691	1314	997
36	CD:G4	1A-7A	177	72	29912	97	24392	103	54
37	CD:G5	1A-7A	230	152	16874	161	6497	45	103
38	CD:G3	1A-7A	146	178	26356	138	22005	90	96
39	CD:G6	1A-7A	129	84	12775	115	2504	91	80
40	CD:C9	1A-7A	2293	2507	8808	3372	2634	3247	2610
41	CD:H10	1A-7A	430	290	29772	306	23992	438	424
42	CD:H11	1A-7A	542	227	24760	324	17835	128	131

Fig. 18B

APPROVED	O.G. FIG.
BY	GLASS (SUBCLASS)
DRAFTSMAN:	






Fig. 19

Title: COMPOSITIONS AND METHODS FOR THE THERAPY, DIAGNOSIS AND MONITORING OF BREAST CANCER
Inventor(s): Gary [REDACTED] et al. Serial No. 09/757,417 Docket No. 210121.47901

Approved	O.G. FIG.
BY	
CLASS	SUBCLASS
DRAFTSMAN	

[REDACTED]

H₃N-[Met] His tag 6aa | Ral12 (short) 30aa | HindIII 2aa | Human gammaglobin (full length) 93aa -C00-

Fig. 20

APPROVED	O.G. FIG.
BY	
DRAFTSMAN	

pCRX1 Expression Screen

Ra12(s)MammFL




Fig. 21